The UK's National Health Service (NHS) faces a significant challenge as the British Medical Association (BMA), a union representing 200,000 doctors, urges its members to limit their use of the Palantir-built NHS Federated Data Platform (FDP). Concerns over data security, patient trust, and Palantir's past work with U.S. immigration enforcement are fueling the BMA's call for a complete break from Palantir technologies within the NHS.
Doctors' Union Voices Concerns
The BMA's stance, articulated in a letter to the British Medical Journal (BMJ), reflects deep-seated unease about entrusting sensitive patient data to a company with Palantir's history. Tom Dolphin, BMA chair of council, stated that doctors "must immediately take steps to explore refusing any non-direct care usage of Palantir's Federated Data Platform." He wants doctors to move away from the platform entirely when a suitable alternative is available.Palantir's spokesperson countered, "Palantir software is helping to deliver better public services in the UK." These services include improving NHS operations, supporting the Royal Navy, and assisting police in combating domestic violence. However, these assurances have not quelled the BMA's anxieties.
Data Sharing and Patient Privacy
This controversy arises amidst broader discussions about data sharing within the NHS. The UK government is proceeding with plans to share anonymized GP patient data with research projects [2]. The NHS app will offer a “dashboard for cancer prevention” that all patients can access, which will utilize information from medical and genomic records.These initiatives, while intended to improve healthcare outcomes, also raise questions about patient privacy and data security. Securing public trust is essential for maximizing the benefits of data-driven healthcare.
Palantir's Position and Growth
Palantir emphasizes the value of its software and its commitment to organic growth [1]. CEO Alex Karp has stated that Palantir does not engage in "intertwined economics" or invest in commodity products. Karp says if a product is necessary, customers do not need to be handed the money to buy it.However, Palantir's customer count growth rate slowed in Q4, marking a deceleration from previous quarters, a potential red flag given the company's high valuation [1]. This slowdown, highlighted by The Motley Fool, is coupled with concerns about its sustainability and potential risks for investors. Palantir's customer count rose 34% year over year during the quarter -- a meaningful slowdown from 45% growth in the prior quarter.
NHS Response
NHS England maintains that no company involved in the FDP can access health and care data without explicit NHS permission. They assert that all data within the platform is under NHS control and will only be used for direct care and planning. Despite these assurances, the BMA remains skeptical.What's Next
- The search for alternative data platforms that address the BMA's concerns is likely to intensify.
- Ongoing scrutiny of Palantir's contracts and data handling practices within the NHS is expected.
- The NHS must convince the BMA that it is committed to data security and patient privacy to restore trust.
Why It Matters
- The dispute highlights the ethical complexities of using data analytics in healthcare, especially when dealing with sensitive patient information.
- The BMA's stance could influence other healthcare organizations' decisions about partnering with Palantir or similar companies.
- This situation underscores the importance of transparency and public engagement in data-sharing initiatives to maintain public trust.
- The incident emphasizes that public perception and ethical considerations can outweigh technical capabilities when implementing new technologies in healthcare.
- Ultimately, patients' willingness to share their data depends on their confidence in the systems and organizations handling it.
